The present teachings relate to devices and methods of use thereof for treating heart failure. An example of the present teachings relates to a device that creates a shunt between two heart chambers thereby allowing blood flow from one to another heart chamber, changing (e.g. reducing) the blood pressure in a heart chamber. The present teachings further relate to devices and methods of use thereof to deliver such a device.
Congestive heart failure (CHF) is a condition affecting millions of people worldwide. CHF results from a weakening or stiffening of the heart muscle that commonly is caused by myocardial ischemia (due to, e.g., myocardial infarction) or cardiomyopathy (e.g., myocarditis, amyloidosis). CHF causes reduced cardiac output and inadequate blood to meet the needs of body tissue.
Treatments for CHF include: (1) pharmacological treatments, (2) assisting systems, and (3) surgical treatment. Pharmacological treatments, e.g., with diuretics, are used to reduce the workload of a heart by reducing blood volume and preload. While drug treatment improves quality of life, it has little effect on survival. Assisting devices, e.g., mechanical pumps, are used to reduce the load on the heart by performing all or part of the pumping function normally done by the heart. However, in a chronic ischemic heart, high-rate pacing may lead to increased diastolic pressure, calcium overload, and damage to the muscle fibers. There are at least three surgical procedures for treating a heart failure: (1) heart transplant, (2) dynamic cardiomyoplasty, and (3) the Batista partial left ventriculectomy. These surgical treatments are invasive and have many limitations.
CHF is generally classified into systolic heart failures (SHF) or diastolic heart failures (DHF). In a SHF, the pumping action of a heart is reduced or weakened. A normal ejection fraction (EF), which is a function of the volume of blood ejected out of the left ventricle (stroke volume) divided by the maximum volume remaining in the left ventricle at the end of the diastole or relaxation phase, is greater than 50%. In systolic heart failure, the EF is decreased to less than 50%. A patient with SHF may have an enlarged left ventricle because of cardiac remodeling developed to maintain an adequate stroke-volume. This pathophysiological phenomenon is often associated with an increased atrial pressure and a left ventricular filling pressure.
DHF is a heart failure without any major valve disease even while the systolic function of the left ventricle is preserved. Generally, DHF is failure of the ventricle to adequately relax and expand, resulting in a decrease in the stroke volume of the heart. Presently, there are very few treatment options for patients suffering from DHF. DHF afflicts between 30% and 70% of those patients with CHF.
There are several known techniques that can be used to treat the symptoms of DHF. Without attempting to characterize the following references, for example, U.S. Pat. No. 8,091,556 by Keren et al. discloses the use of an interatrial pressure relief shunt with a valve and a tissue affixation element at each end of the shunt; and United States Patent Application Publication No. 20050165344 by Dobak discloses a pressure relief system with an interatrial septal conduit with an emboli barrier or trap mechanism to prevent cryptogenic stroke due to thrombi or emboli crossing the conduit into the left sided circulation. Dobak also discloses a conduit with a one-way valve which directs blood flow from the left atrium to the right atrium.
The constantly evolving nature of heart failure represents a significant challenge for treatment. Therefore, there is a need for novel and adaptable methods and devices for treating DHF, for example, by creating a pressure relief shunt which can be retrieved, repositioned, adjusted, expanded, contracted, occluded, sealed and/or otherwise altered as required to treat the patient.
One aspect of the present teachings provides devices for regulating blood pressure in a heart chamber. In various embodiments, the device for regulating blood pressure includes a transeptal tissue coring device for removing tissue from the heart, comprising a tissue incising element and a tissue stabilizer. In some embodiments, the tissue incising element comprises a proximal portion, a distal portion with a sharp edge at the distal end, and a longitudinal lumen extending from the proximal portion to the distal portion. In some embodiments, the tissue stabilizer comprises an elongated body, a distal portion, and a plurality of tissue supporting struts at the distal portion. In certain embodiments, the plurality of tissue supporting struts each comprises a fixed end attached to the elongated body and a free end configured to move radially away from the elongated body of the tissue stabilizer.
In various embodiments, the tissue stabilizer is slidably disposed within the longitudinal lumen of the tissue incising element. In some embodiments, the tissue supporting struts are stowed radially along the elongated body of the tissue stabilizer when the distal portion of the tissue stabilizer is constrained within the longitudinal lumen of the tissue incising element. In other embodiments, the tissue supporting struts expand radially to form a tissue supporting surface when the distal portion of the tissue stabilizer is exposed outside of the longitudinal lumen of the tissue incising element.
In various embodiments, a transseptal tissue coring device for removing tissue from the heart comprises a tissue incising element and a tissue stabilizer. In some embodiments, the tissue stabilizer comprises an elongated body, a distal portion, and a plurality of tissue supporting struts at the distal portion. In certain embodiments, the tissue supporting struts are formed by a plurality of slits along the elongated body of the tissue stabilizer.
In various embodiments, the tissue stabilizer is slidably disposed within the longitudinal lumen of the tissue incising element. In some embodiments, the tissue supporting struts are lengthened along the elongated body of the tissue stabilizer when the distal portion of the tissue stabilizer is constrained within the longitudinal lumen of the tissue incising element. In other embodiments, the tissue supporting struts are shortened and expand radially to form a tissue supporting surface when the distal portion of the tissue stabilizer is exposed outside of the longitudinal lumen of the tissue incising element.
Another aspect of the present teachings provides a method of percutaneously removing tissue from the heart. In various embodiments, the method comprises providing a transseptal tissue coring device comprising a tissue incising element with a sharp edge at a distal end and a tissue stabilizer having a plurality of tissue supporting struts at a distal portion of the tissue stabilizer where the tissue stabilizer is slidably disposed within an elongated lumen of the tissue incising element; advancing the transseptal tissue coring device to a proximity of the atrial septum; expanding the tissue supporting struts of the tissue stabilizer radially and positioning the tissue stabilizer against the atrial septum inside the left atrium; advancing the tissue incising element distally so that the sharp edge at the distal end of the tissue incising element is positioned against the atrial septum inside the right atrium; making an incision in the atrial septum by using the tissue incising element and/or the tissue stabilizer; and retracting the tissue stabilizer proximally, allowing the distal portion of the tissue stabilizer to slide back into the tissue incising element and the tissue supporting struts carrying the removed septal tissue to fold radially and distally, where the removed septal tissue is captured inside the elongated lumen of the tissue incising element.
Another aspect of the present teachings provides a method of percutaneously removing tissue from the heart. In various embodiments, the method comprises providing a delivery sheath and a transseptal tissue coring device, wherein the delivery sheath comprises a distal end and a longitudinal lumen, the transseptal tissue coring device is slidably disposed within the longitudinal lumen of the delivery sheath, wherein the transseptal tissue coring device comprises a tissue incising element with a sharp edge at a distal end and a tissue stabilizer having a plurality of tissue supporting struts at a distal portion, where the tissue stabilizer is slidably disposed within an elongated lumen of the tissue incising element; advancing the transseptal tissue coring device to a proximity of the atrial septum; expanding the tissue supporting struts of the tissue stabilizer radially and positioning the tissue stabilizer against the atrial septum inside the left atrium; advancing the tissue incising element distally so that the sharp edge at the distal end of the tissue incising element is positioned against the atrial septum inside the right atrium; incising the septal tissue using the tissue incising element and/or the tissue stabilizer; advancing the delivery sheath distally so that the distal end of the delivery sheath is at the proximity of the atrial septal tissue: retracting the tissue incising element proximally; and retracting the tissue stabilizer proximally to allow the distal portion of the tissue stabilizer to slide back into the delivery sheath and the tissue supporting struts carrying the removed septal tissue to fold radially and distally, wherein the removed septal tissue is captured inside the elongated lumen of the tissue incising element.
Certain specific details are set forth in the following description and drawings to provide an understanding of various embodiments of the present teachings. Those with ordinary skill in the relevant art will understand that they can practice other embodiments of the present teachings without one or more of the details described below. Finally, while various processes are described with reference to steps and sequences in the following disclosure, the steps and sequences of steps should not be taken as required to practice all embodiments of the present teachings.
As used herein, the terms “radially outward” and “radially away” means any direction which is not parallel with the central axis. For example, considering a cylinder, a radial outward member could be a piece of wire or a loop of wire that is attached or otherwise operatively coupled to the cylinder that is oriented at an angle greater than 0° relative to the central longitudinal axis of the cylinder.
As used herein, the term “lumen” means a canal, duct, generally tubular space or cavity in the body of a subject, including veins, arteries, blood vessels, capillaries, intestines, and the like. The term “lumen” can also refer to a tubular space in a catheter, a sheath, or the like in a device.
As used herein, the term “proximal” shall mean closest to the operator (less into the body) and “distal” shall mean furthest from the operator (further into the body). In positioning a medical device inside a patient, “distal” refers to the direction away from a catheter insertion location and “proximal” refers to the direction near the insertion location.
The exemplary devices described in various embodiments each is used to create an aperture or a shunt on the atrial septum, which allows fluid communication between the left and right atria and releases the left atrium pressure. It, however, should be appreciated that the present teachings are also applicable for use in other parts of the anatomy, or for other indications. For instance, a device, such as one described in the present teachings, could be used to create a shunt between the coronary sinus and the left atrium for the same indication. Additionally, a shunt such as one described in the present teachings could be placed between the azygous vein and the pulmonary vein.
The following description refers to
The present teachings relate to a transseptal tissue coring device and methods of using such a device for percutaneously removing a certain size and/or amount of tissue from the atrial septum, producing an aperture in the atrial septum, and creating a left-to-right blood shunt in the atria. In some embodiments, the device includes an elongated tubular body with a tissue incising element at its distal end and a tissue stabilizer slidably disposed within the tubular lumen of the elongated body during delivery. The tissue stabilizer is configured to extend through an aperture on the septum, stabilize, and support the septum from the opposite side of an incision as described herein.
According to various embodiments, the tissue incising element is adapted at the distal end of the elongated tubular body. In some embodiments, the tissue incising element includes a proximal end, a distal end, and a body extending between the proximal end and the distal end. In some embodiments, the proximal end of the tissue incising element attaches to the distal end of the elongated tubular body and the distal end of the tissue incising element includes a sharp edge along the circumference configured for incising tissue. In some embodiments, the body of the tissue incising element has a tubular shape. In other embodiments, the body of the tissue incising element has a collapsible cone shape.
In various embodiments, a tissue stabilizer of the present teachings includes an elongated body with a distal portion and a proximal portion. In some embodiments, the distal portion of the tissue stabilizer has at least two radially expandable tissue supporting struts. In various embodiments, the tissue stabilizer has a pre-formed radially expanded configuration and a stowed configuration.
In various embodiments, a transseptal tissue coring device of the present teachings tracks over a guide wire, for example, positioned across a tissue beforehand. In some embodiments, the tissue stabilizer includes a tissue piercing element. For example, the tissue piercing element can be used to create an aperture on the septum.
In various embodiments, a transseptal tissue coring device of the present teachings includes an elongated delivery profile where the tissue supporting struts of the tissue stabilizer are stowed radially inward so that the entire tissue stabilizer is slidably disposed within the elongated lumen of the elongated member. In other embodiments, the transseptal tissue coring device includes an expanded deployed profile where the tissue stabilizer is exposed distally outside of the tissue incising element and the tissue supporting struts expand radially.
In various embodiments, a tissue coring device of the present teachings is configured to be percutaneously delivered into the right atrium, across the atrial septum, and inside the left atrium. In some embodiments, the tissue stabilizer supports a piece of septal tissue while the tissue incising element incises the tissue. In some embodiments, the tissue stabilizer captures and percutaneously removes the detached tissue from the body. In such embodiments, the aperture generated with the tissue coring device described herein allows blood flow from one side of the septum to the other. In some embodiments, the aperture has a minimum size of 3-4 mm in general diameter, so that the aperture will not heal itself, i.e. re-closure, over time, thereby allowing a continuous pressure relief to the left heart over time. In various other embodiments, the device is used with a delivery system.
In some embodiments, the tissue coring device is percutaneously delivered via a delivery sheath (30). The delivery sheath (30) includes a proximal end (not shown), a distal end (31), and a longitudinal lumen (22). As described herein, the tissue coring device (10) includes an elongated delivery profile, a deployed profile, and a collapsed tissue retrieval profile. In its delivery profile, the entire tissue coring device (10) is slidably disposed within the lumen (22) of the delivery sheath (30). In its deployed profile, the tissue coring device (10) extends distally and the tissue incising element (12) and the tissue supporting/gripping element each exits outside of the lumen (22) of the delivery sheath (30) and resume its intended configuration. In its tissue retrieval profile, the tissue incising element (12) is pulled proximally back inside the lumen (22) of the delivery sheath (30) and the tissue supporting/gripping element collapses and is pulled proximally inside the lumen (26) of the tissue incising element (12) and/or the lumen (22) of the delivery sheath (30).
In some embodiments, the tissue incising element and the tissue stabilizer are incorporated with radiopaque markers so the devices may more easily be visualized using a radiographic imaging equipment such as with x-ray or fluoroscopic techniques. In some other embodiments, the entire transseptal tissue coring device is made of a radiopaque material. In some embodiments, the radiopaque marker/material is made of tantalum, tungsten, platinum irridium, gold, alloys of these materials or other materials that are known to those skilled in the art. In other embodiments, radiopaque markers comprising cobalt, fluorine or numerous other paramagnetic materials or other MR visible materials that are known to those skilled in the arts are incorporated in the tissue incising element and/or the tissue stabilizer. In certain embodiments, the paramagnetic material or MR visible material is incorporated with a radiopaque material. For example, two or more of a paramagnetic material, a MR visible material, an X-ray material, or a fluoroscopic material, each of which is described herein, can be arranged in alternating locations on the device to enable both x-ray and MR imaging of the device.
According to another embodiment, the tissue stabilizer (14) can also be slidably disposed within a separate sheath which can slide through the conduit funned by the elongated body (8) and the tissue incising element (12). In such an embodiment, the tissue stabilizer (14) is deployed distally further away from the tissue incising element (12). One example of such a sheath (33) is shown in
According to some embodiments, during a tissue retrieval as described herein, the tissue stabilizer (14) is pulled proximally back inside the axial lumen (26) of the tissue incising element (12) from the distal end (24) of the tissue incising element (12); and, constrained by the lumen of the tissue incising element (12), the tissue supporting struts (36) fold distally inward and the tissue stabilizer (14) resumes the elongated profile. Alternatively, the tissue stabilizer (14) is pulled proximally into the lumen of a sheath from its distal end and, constrained by the sheath, the tissue supporting struts (36) fold distally inward and the tissue stabilizer (14) resumes its elongated profile.
In an alternative embodiment, slits (78) may be cut at an angle such that they are helically disposed along the tubular body (70), as illustrated in
According to some embodiments, during a tissue retrieval described herein, the tissue stabilizer (54) is pulled proximally back inside the axial lumen (26) of the tissue incising element (12) from its distal end (24) and, constrained by the tissue incising element, the tissue supporting struts (76) fold inward radially and the tissue stabilizer resumes its elongated profile. In an alternative embodiment, during tissue retrieval, the deployed tissue supporting struts (76) are forced by the distal end of the tissue incising element or a retrieval sheath to stretch longitudinally and reduce its profile as it is pulled proximally into the axial lumen of the tissue incising element or the sheath.
Although specific slitting patterns and shapes have been described here, one reasonably skilled in the art would understand that other designs can be incorporated without any undue experimentation to form a tissue stabilizer so long as each of such designs provides an elongated delivery profile and an expanded deployed profile. Thus, the specific embodiments described herein should not be viewed as limiting.
According to some embodiments, the tissue supporting struts (36, 76) transition from an elongated delivery profile to an expanded deployed profile by elastic recovery or thermal-shape transformation. In some embodiments, if a sufficiently elastic and resilient material is used, the struts (36, 76) can be pre-formed into the deployed shape and then elastically deformed and stowed during delivery. After the device is successfully delivered, it recovers to the preformed shape by the elastically recovery. In other embodiments, the tissue supporting struts (36, 76) may be manually expanded to the desired deployment shape and heat set in an oven while maintained in such a desired shape to memorize the shape. The struts (36, 76) are then distorted into a generally straightened profile during a delivery process and resume their intended deployed profile in vivo. In some embodiments the tissue supporting struts may be distorted from a generally straightened profile to their intended deployed profile in vivo by use of a wire attached to the most distal end. For example, the struts can be distorted into the deployed profile by moving the wire proximally to reduce the axial length of the distal portion and move the struts radially outward.
According to various embodiments, the tissue stabilizer includes at least two tissue supporting struts (36, 76). Devices according to the present teachings may include any number of tissue supporting struts (36, 76). In some embodiments, the tissue stabilizer includes eight tissue supporting struts (36, 76), as illustrated in
According to some embodiments, during a tissue coring, the tissue stabilizer (14, 54) is deployed and positioned against one side of the tissue and the tissue incising element (12, 52) is deployed and positioned against the opposite side of the tissue. Thus, the tissue stabilizer (14, 54) provides support to the septal tissue during a tissue coring. In some embodiments, the deployed tissue stabilizer (14, 54) has a general size greater than the general size of the surface formed by the cutting edge of the tissue incising element (12, 52) so that a substantial area of the tissue to be cut is supported by the tissue supporting struts (36, 76). In some embodiments, the deployed tissue supporting struts form a surface 50-4000% greater than the surface formed by the cutting edge of the tissue incising element (12, 52). In some embodiments, the deployed tissue supporting struts (36, 76) form a surface with a general diameter of 5 mm to 25 mm. In other embodiments, the deployed tissue supporting struts (36, 76) form a tissue supporting surface with a general diameter 50-600% greater than the general diameter of the surface formed by the cutting edge of the tissue incising element (12, 52).
The tissue stabilizer (14, 54, 64, 94) can be made of a biocompatible metal or polymer. In some embodiments, the tissue stabilizer (14, 54, 64, 94) in whole or in part is made of an elastic material, a super-elastic material, or a shape-memory alloy which allows selected portions to distort into a generally straightened profile during the delivery process and resume and maintain its intended profile in vivo once deployed. In some embodiments, part or all of the tissue stabilizer (14, 54, 64, 94) is made of stainless steel, nitinol, Titanium, Elgiloy, Vitalium, Mobilium, Ticonium, Platinore, Stellite, Tantalum, Platium, Hastelloy, CoCrNi alloys (e.g., trade name Phynox). MP35N, or CoCrMo alloys or other metallic alloys. Alternatively, in such other embodiments, part or the entire device is made of a polymer such as PTFE, UHMPE, HDPE, polypropylene, polysulfone, polymethane, Pebax® or another biocompatible plastic.
In various embodiments, the tissue incising element is configured to move distally or proximally by a clinician from outside of the body. In various embodiments, the tissue incising element is configured to rotate clock-wise or counter clock-wise by a clinician from outside of the body. The mechanism for percutaneously moving a medical device and/or the tissue stabilizer distally or proximally or rotating the medical device in a clock-wise or counter clock-wise fashion are known in the art. In some embodiments, the tissue incising element also includes a cutting edge for removing tissue. The cutting edge and use thereof is discussed herein, including as shown in
In various embodiments, the cross section of the tissue incising element (12) is circular or polygonal, such as square or hexagonal. In some embodiments, the cross section of the tissue incising element (12) is substantially uniform throughout its length. In other embodiments, the cross section of the tissue incising element (12) varies throughout the length.
In various embodiments, the tissue is removed by the a direct force “F1”, as shown in
In various embodiments, the tissue incising element (120) is preformed into its expanded profile and can transition from its expanded profile to its collapsed profile. In some embodiments, the cone shaped body includes one or more slits (128) and one or more flaps (130, 132). In some embodiments, some of these slits (128) are along a portion or the entire length of the cone shaped body (122) of the tissue incising element (120). In some embodiments, portions of the adjacent flaps (130, 132) of the tissue incising element (120) overlap when the tissue incising element (120) is in its collapsed profile.
Choosing a method of making a tissue incising element depends mainly on the raw material. In some embodiments, wires are formed into a tissue incising element (160) in various ways by selecting from conventional wire forming techniques, including coiling, braiding, or knitting. In certain embodiments, subsequent welding at specific locations produces a closed-cell wire tissue incising element (160) with an increased longitudinal stability. In other embodiments, a tissue incising element (160) is produced by laser cutting or photochemical etching of a tubing. Similar to what has been described in connection with
In this particular example, the distal end (172) does not include a continuous distal edge. As shown in
Now referring to
In some embodiments, the bevel described herein is formed by removing a portion of the luminal wall by using a proper method, including grinding. According to some embodiments, the edge is formed by a straight bevel as illustrated in
In some embodiments, the mechanical cutting action of the tissue incising element may be coupled with a radio frequency energy source. For example, the radio frequency energy source can be used to thermally ablate tissue in contact with the tissue incising element. Without intending to limit the scope of the present teachings, the ablation action is used to reduce the force required to advance the tissue incisor through the septal wall.
According to some embodiments, the cutting edge (108) of a tissue incising element discussed in connection with
In various embodiments, the elongated body (8) and the tissue incising element are parts of an uniform and monolithic body. In such embodiments, the entire elongated body (8) and the tissue incising element is made of one material strong enough for the tissue cutting and flexible enough to be delivered percutaneously into the body. In some embodiments, the tissue incising element is a separate component and is attached to the distal end of the elongated body (8). In such embodiments, the elongated body (8) is made of a flexible material such as polyether-block co-polyamide polymers, for example Pebax™; polyethylene, polytetrafluoroethylene (EPTFE), Fluorinatedethylenepropylene (FEP), polyurethane etc. In addition, in such embodiments, the tissue incising element is made of a hard material such as stainless steel, titanium, ceramic, alloy metal etc. The attachment of the incising element and the elongated body can be achieved by a variety of means, including a mechanical means, for example an interference connection or a threaded connection between the distal portion and the tubular body: an energy means such as heat, laser, ultrasonic, or other types of welding etc; or a chemical means such as adhesive bonding, etc. Other methods of attachment known to those skilled in the art can also be incorporated.
Each of the exemplary tissue stabilizer described in
In some embodiments, the aperture created by a transseptal tissue coring device of the present teachings allows fluid communication between the left and right atria, thereby releasing the left heart pressure. In many embodiments, in order to provide a continuous relief to the left atrium, it is preferred that the aperture between the right and left atria does not re-close itself during a healing process. In certain embodiments, a tissue incising element of the present teachings has a cutting edge with a minimum diameter so that the aperture produced by the incising element also has a minimum size. For example, the cutting edge of the tissue incising element can have a general diameter of 4 mm to 12 mm.
Another aspect of the present teachings relate to methods of delivering and deploying a transseptal coring device. One ordinarily skilled in the art would understand that what is described below are only exemplary methods of percutaneously delivering a transseptal tissue coring device of the present teachings and that other methods can also be used without departing from the spirit of the present teachings. Accordingly, the disclosure should not be viewed as limiting. For example, a transseptal tissue coring device can be delivered without a delivery sheath or a tissue stabilizer can penetrate the septal tissue at its distal end, instead of tracking over a guide wire affixed in the septum beforehand.
Additionally, one ordinarily skilled in the art would also understand that although methods and processes of delivering and/or deploying a transseptal tissue coring device is described with reference to the exemplary devices described in
According to some embodiments, a transseptal tissue coring device of the present teachings is delivered through a standard right heart catheterization procedure. In such a procedure, the device is delivered through an insertion site on the femoral vein through the inferior vena cava to the right atrium. In some embodiments, a delivery sheath is used to transport a transseptal tissue coring device to a treatment location. In some embodiments, a guide wire is also used to locate a treatment site and assist the delivery of a transseptal tissue coring device to the treatment site.
Referring to
Still referring to
In yet another embodiment of the present teachings, as shown in
Now referring to
In various embodiments, the deployment of a tissue incising element depends on the deployment of a tissue stabilizer. In various embodiments, the deployment of a tissue incising element is independent from the deployment of a tissue stabilizer. In some embodiments, a tissue incising element is deployed simultaneously as a tissue stabilizer. In some embodiments, a tissue incising element is deployed after the deployment of a tissue stabilizer.
In various embodiments, where a guide wire (130) is not used during a device delivery, a separate transseptal puncture needle can be used to create a small incision on the septum for a tissue stabilizer to cross over. In such embodiments, the tissue stabilizer can slide over the transseptal puncture needle. In other embodiments, the distal end of the tissue stabilizer can be used to perforate the atrial septum and allow the rest of the distal portion of the tissue stabilizer to cross the atrial septum. One reasonably skilled in the art would understand that other devices and/or methods can also be used deliver a tissue stabilizer across the atrial septum. For example, a radio frequency energy source can be coupled to a tissue stabilizer such that the distal end of the tissue stabilizer can create a small hole to allow the distal portion of the tissue stabilizer to cross over the atrial septum.
In an alternative embodiment, as illustrated in
On reasonably skilled in the art would understand that a control mechanism can be used to manage the motion of the delivery sheath, the tissue incising element, the tissue stabilizer, and the guide wire, each of which is described herein. In some embodiments, each of the delivery sheath, the tissue incising element, the tissue stabilizer, and the guide wire moves independently. In other embodiments, motions of the delivery sheath, the incising element, the tissue stabilizer, and the guide wire can be linked to one another for convenience.
The present teachings are capable of other embodiments or of being practiced or carried out in various other ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which these present teachings belong. Methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present teachings. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
This application claims the benefit of and priority to U.S. Provisional Patent Application No. 61/778,382, filed on Mar. 12, 2013. The entire content of the provisional application is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4018228 | Goosen | Apr 1977 | A |
4705507 | Boyles | Nov 1987 | A |
5100423 | Fearnot | Mar 1992 | A |
5108420 | Marks | Apr 1992 | A |
5171233 | Amplatz et al. | Dec 1992 | A |
5334217 | Das | Aug 1994 | A |
5429144 | Wilk | Jul 1995 | A |
5556408 | Farhat | Sep 1996 | A |
5578045 | Das | Nov 1996 | A |
5693090 | Unsworth et al. | Dec 1997 | A |
5702412 | Popov et al. | Dec 1997 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5824071 | Nelson et al. | Oct 1998 | A |
5876436 | Vanney et al. | Mar 1999 | A |
6050936 | Schweich et al. | Apr 2000 | A |
6077281 | Das | Jun 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6156055 | Ravenscroft | Dec 2000 | A |
6190353 | Makower et al. | Feb 2001 | B1 |
6193734 | Bolduc et al. | Feb 2001 | B1 |
6258119 | Hussein et al. | Jul 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6350277 | Kocur | Feb 2002 | B1 |
6355052 | Neuss et al. | Mar 2002 | B1 |
6355056 | Pinheiro | Mar 2002 | B1 |
6383195 | Richard | May 2002 | B1 |
6395017 | Dwyer et al. | May 2002 | B1 |
6402777 | Globerman et al. | Jun 2002 | B1 |
6409716 | Sahatjian et al. | Jun 2002 | B1 |
6440152 | Gainor et al. | Aug 2002 | B1 |
6454795 | Chuter | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6468303 | Amplatz et al. | Oct 2002 | B1 |
6527746 | Oslund et al. | Mar 2003 | B1 |
6626936 | Stinson | Sep 2003 | B2 |
6641610 | Wolf et al. | Nov 2003 | B2 |
6645143 | Van Tassel et al. | Nov 2003 | B2 |
6666885 | Moe | Dec 2003 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6837901 | Rabkin et al. | Jan 2005 | B2 |
6866679 | Kusleika | Mar 2005 | B2 |
6911037 | Gainor et al. | Jun 2005 | B2 |
6913614 | Marino et al. | Jul 2005 | B2 |
6936058 | Forde et al. | Aug 2005 | B2 |
6979343 | Russo et al. | Dec 2005 | B2 |
7001409 | Amplatz et al. | Feb 2006 | B2 |
7097653 | Freudenthal et al. | Aug 2006 | B2 |
7105024 | Richelsoph | Sep 2006 | B2 |
7159593 | McCarthy et al. | Jan 2007 | B2 |
7226466 | Opolski | Jun 2007 | B2 |
7317951 | Schneider et al. | Jan 2008 | B2 |
7338514 | Wahr et al. | Mar 2008 | B2 |
7419498 | Opolski et al. | Sep 2008 | B2 |
7445630 | Lashinski et al. | Nov 2008 | B2 |
7473266 | Glaser | Jan 2009 | B2 |
7485141 | Majercak et al. | Feb 2009 | B2 |
7524330 | Berreklouw | Apr 2009 | B2 |
7530995 | Quijano et al. | May 2009 | B2 |
7625392 | Coleman et al. | Dec 2009 | B2 |
7658747 | Forde et al. | Feb 2010 | B2 |
7699297 | Cicenas et al. | Apr 2010 | B2 |
7766966 | Richelsoph | Aug 2010 | B2 |
7819890 | Russo et al. | Oct 2010 | B2 |
7842026 | Cahill et al. | Nov 2010 | B2 |
7871419 | Devellian et al. | Jan 2011 | B2 |
7927370 | Webler et al. | Apr 2011 | B2 |
7976564 | Blaeser et al. | Jul 2011 | B2 |
8034061 | Amplatz et al. | Oct 2011 | B2 |
8043360 | McNamara et al. | Oct 2011 | B2 |
8048147 | Adams | Nov 2011 | B2 |
8070708 | Rottenberg et al. | Dec 2011 | B2 |
8091556 | Keren et al. | Jan 2012 | B2 |
8157860 | McNamara et al. | Apr 2012 | B2 |
8172896 | McNamara et al. | May 2012 | B2 |
8252042 | McNamara et al. | Aug 2012 | B2 |
8460372 | McNamara et al. | Jun 2013 | B2 |
20010029368 | Berube | Oct 2001 | A1 |
20020029061 | Amplatz et al. | Mar 2002 | A1 |
20020062135 | Mazzocchi et al. | May 2002 | A1 |
20020072765 | Mazzocchi et al. | Jun 2002 | A1 |
20020077698 | Peredo | Jun 2002 | A1 |
20020082525 | Oslund et al. | Jun 2002 | A1 |
20020082613 | Hathaway et al. | Jun 2002 | A1 |
20020095172 | Mazzocchi et al. | Jul 2002 | A1 |
20020095173 | Mazzocchi et al. | Jul 2002 | A1 |
20020143289 | Ellis et al. | Oct 2002 | A1 |
20020161424 | Rapacki et al. | Oct 2002 | A1 |
20020161432 | Mazzucco et al. | Oct 2002 | A1 |
20020165606 | Wolf et al. | Nov 2002 | A1 |
20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
20020173742 | Keren et al. | Nov 2002 | A1 |
20020177894 | Acosta et al. | Nov 2002 | A1 |
20020183826 | Dorn et al. | Dec 2002 | A1 |
20020198563 | Gainor et al. | Dec 2002 | A1 |
20040044351 | Searle | Mar 2004 | A1 |
20040087937 | Eggers et al. | May 2004 | A1 |
20040093075 | Kuehne | May 2004 | A1 |
20040102719 | Keith et al. | May 2004 | A1 |
20040111095 | Gordon et al. | Jun 2004 | A1 |
20040133236 | Chanduszko et al. | Jul 2004 | A1 |
20040143292 | Marino | Jul 2004 | A1 |
20040162514 | Alferness et al. | Aug 2004 | A1 |
20040176788 | Opolski | Sep 2004 | A1 |
20040193261 | Berreklouw | Sep 2004 | A1 |
20040206363 | McCarthy et al. | Oct 2004 | A1 |
20040220653 | Borg et al. | Nov 2004 | A1 |
20040236308 | Herweck et al. | Nov 2004 | A1 |
20040243143 | Corcoran et al. | Dec 2004 | A1 |
20040267306 | Blaeser et al. | Dec 2004 | A1 |
20050049692 | Numamoto et al. | Mar 2005 | A1 |
20050065548 | Marino et al. | Mar 2005 | A1 |
20050065589 | Schneider et al. | Mar 2005 | A1 |
20050070934 | Tanaka et al. | Mar 2005 | A1 |
20050075655 | Bumbalough et al. | Apr 2005 | A1 |
20050075665 | Brenzel | Apr 2005 | A1 |
20050080400 | Corcoran et al. | Apr 2005 | A1 |
20050080430 | Wright, Jr. | Apr 2005 | A1 |
20050148925 | Rottenberg et al. | Jul 2005 | A1 |
20050165344 | Dobak | Jul 2005 | A1 |
20050187616 | Realyvasquez | Aug 2005 | A1 |
20050240205 | Berg et al. | Oct 2005 | A1 |
20050267523 | Devellian et al. | Dec 2005 | A1 |
20050273075 | Kulevitch et al. | Dec 2005 | A1 |
20050288722 | Eigler et al. | Dec 2005 | A1 |
20060004434 | Forde et al. | Jan 2006 | A1 |
20060009715 | Khairkhahan et al. | Jan 2006 | A1 |
20060009800 | Christianson et al. | Jan 2006 | A1 |
20060122646 | Corcoran et al. | Jun 2006 | A1 |
20060122647 | Callaghan et al. | Jun 2006 | A1 |
20060136043 | Cully et al. | Jun 2006 | A1 |
20060155305 | Freudenthal et al. | Jul 2006 | A1 |
20060184088 | Van Bibber et al. | Aug 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060247680 | Amplatz et al. | Nov 2006 | A1 |
20060253184 | Amplatz | Nov 2006 | A1 |
20060276882 | Case et al. | Dec 2006 | A1 |
20070016250 | Blaeser et al. | Jan 2007 | A1 |
20070027528 | Agnew | Feb 2007 | A1 |
20070038295 | Case et al. | Feb 2007 | A1 |
20070043431 | Melsheimer | Feb 2007 | A1 |
20070088388 | Opolski et al. | Apr 2007 | A1 |
20070118207 | Amplatz et al. | May 2007 | A1 |
20070123934 | Whisenant et al. | May 2007 | A1 |
20070168019 | Amplatz et al. | Jul 2007 | A1 |
20070185513 | Woolfson et al. | Aug 2007 | A1 |
20070209957 | Glenn et al. | Sep 2007 | A1 |
20070225759 | Thommen et al. | Sep 2007 | A1 |
20070265658 | Nelson et al. | Nov 2007 | A1 |
20070270741 | Hassett et al. | Nov 2007 | A1 |
20070282157 | Rottenberg et al. | Dec 2007 | A1 |
20080015619 | Figulla et al. | Jan 2008 | A1 |
20080033425 | Davis et al. | Feb 2008 | A1 |
20080033543 | Gurskis et al. | Feb 2008 | A1 |
20080039804 | Edmiston et al. | Feb 2008 | A1 |
20080039881 | Greenberg | Feb 2008 | A1 |
20080039922 | Miles et al. | Feb 2008 | A1 |
20080058940 | Wu et al. | Mar 2008 | A1 |
20080071135 | Shaknovich | Mar 2008 | A1 |
20080086168 | Cahill | Apr 2008 | A1 |
20080103508 | Karakurum | May 2008 | A1 |
20080119891 | Miles et al. | May 2008 | A1 |
20080125861 | Webler et al. | May 2008 | A1 |
20080154302 | Opolski et al. | Jun 2008 | A1 |
20080154351 | Leewood et al. | Jun 2008 | A1 |
20080172123 | Yadin | Jul 2008 | A1 |
20080183279 | Bailey et al. | Jul 2008 | A1 |
20080188880 | Fischer | Aug 2008 | A1 |
20080188888 | Adams et al. | Aug 2008 | A1 |
20080215008 | Nance et al. | Sep 2008 | A1 |
20080228264 | Li et al. | Sep 2008 | A1 |
20080249612 | Osborne et al. | Oct 2008 | A1 |
20080262592 | Jordan et al. | Oct 2008 | A1 |
20080312679 | Hardert et al. | Dec 2008 | A1 |
20090018562 | Amplatz et al. | Jan 2009 | A1 |
20090025820 | Adams | Jan 2009 | A1 |
20090030495 | Koch | Jan 2009 | A1 |
20090054805 | Boyle, Jr. | Feb 2009 | A1 |
20090062841 | Amplatz et al. | Mar 2009 | A1 |
20090082803 | Adams et al. | Mar 2009 | A1 |
20090099647 | Glimsdale et al. | Apr 2009 | A1 |
20090112050 | Farnan et al. | Apr 2009 | A1 |
20090112244 | Freudenthal et al. | Apr 2009 | A1 |
20090131978 | Gainor et al. | May 2009 | A1 |
20090171386 | Amplatz et al. | Jul 2009 | A1 |
20090187214 | Amplatz et al. | Jul 2009 | A1 |
20090209855 | Drilling et al. | Aug 2009 | A1 |
20090210047 | Amplatz et al. | Aug 2009 | A1 |
20090210048 | Amplatz et al. | Aug 2009 | A1 |
20090234443 | Ottma et al. | Sep 2009 | A1 |
20090264991 | Paul et al. | Oct 2009 | A1 |
20090270840 | Miles et al. | Oct 2009 | A1 |
20090270909 | Oslund et al. | Oct 2009 | A1 |
20100022940 | Thompson | Jan 2010 | A1 |
20100023046 | Heidner et al. | Jan 2010 | A1 |
20100023048 | Mach | Jan 2010 | A1 |
20100023121 | Evdokimov et al. | Jan 2010 | A1 |
20100030321 | Mach | Feb 2010 | A1 |
20100049307 | Ren | Feb 2010 | A1 |
20100057192 | Celermajer | Mar 2010 | A1 |
20100063578 | Ren et al. | Mar 2010 | A1 |
20100094335 | Gerberding et al. | Apr 2010 | A1 |
20100106235 | Kariniemi et al. | Apr 2010 | A1 |
20100121370 | Kariniemi | May 2010 | A1 |
20100131053 | Agnew | May 2010 | A1 |
20100179491 | Adams et al. | Jul 2010 | A1 |
20100211046 | Adams et al. | Aug 2010 | A1 |
20100234881 | Blaeser et al. | Sep 2010 | A1 |
20100249909 | McNamara et al. | Sep 2010 | A1 |
20100249910 | McNamara et al. | Sep 2010 | A1 |
20100256548 | McNamara et al. | Oct 2010 | A1 |
20100256753 | McNamara et al. | Oct 2010 | A1 |
20100298755 | McNamara et al. | Nov 2010 | A1 |
20100324588 | Miles et al. | Dec 2010 | A1 |
20110004239 | Russo et al. | Jan 2011 | A1 |
20110004296 | Lutter et al. | Jan 2011 | A1 |
20110022079 | Miles et al. | Jan 2011 | A1 |
20110071623 | Finch et al. | Mar 2011 | A1 |
20110071624 | Finch et al. | Mar 2011 | A1 |
20110093062 | Cartledge et al. | Apr 2011 | A1 |
20110106149 | Ryan et al. | May 2011 | A1 |
20110112633 | Devellian et al. | May 2011 | A1 |
20110130784 | Kusleika | Jun 2011 | A1 |
20110190874 | Celermajer et al. | Aug 2011 | A1 |
20110213364 | Davis et al. | Sep 2011 | A1 |
20110218477 | Keren et al. | Sep 2011 | A1 |
20110218478 | Keren et al. | Sep 2011 | A1 |
20110218479 | Rottenberg et al. | Sep 2011 | A1 |
20110218480 | Rottenberg et al. | Sep 2011 | A1 |
20110218481 | Rottenberg | Sep 2011 | A1 |
20110257723 | McNamara et al. | Oct 2011 | A1 |
20110283871 | Adams | Nov 2011 | A1 |
20110295182 | Finch et al. | Dec 2011 | A1 |
20110295183 | Finch et al. | Dec 2011 | A1 |
20110295362 | Finch et al. | Dec 2011 | A1 |
20110295366 | Finch et al. | Dec 2011 | A1 |
20110306916 | Nitzan et al. | Dec 2011 | A1 |
20110307000 | Amplatz et al. | Dec 2011 | A1 |
20120053686 | McNamara et al. | Mar 2012 | A1 |
20120130301 | McNamara et al. | May 2012 | A1 |
20120165928 | Nitzan et al. | Jun 2012 | A1 |
20120259263 | Celermajer | Oct 2012 | A1 |
20120265296 | McNamara et al. | Oct 2012 | A1 |
20120289882 | McNamara et al. | Nov 2012 | A1 |
20120290062 | McNamara et al. | Nov 2012 | A1 |
20130041359 | Asselin | Feb 2013 | A1 |
20130178783 | McNamara et al. | Jul 2013 | A1 |
20130178784 | McNamara et al. | Jul 2013 | A1 |
20130184633 | McNamara et al. | Jul 2013 | A1 |
20130184634 | McNamara et al. | Jul 2013 | A1 |
20130204175 | Sugimoto | Aug 2013 | A1 |
20130231737 | McNamara et al. | Sep 2013 | A1 |
20130267885 | Celermajer et al. | Oct 2013 | A1 |
20130281988 | Magnin | Oct 2013 | A1 |
20140012181 | Sugimoto | Jan 2014 | A1 |
Number | Date | Country |
---|---|---|
1470785 | Oct 2004 | EP |
2537490 | Dec 2012 | EP |
9527448 | Oct 1995 | WO |
2008058940 | May 2008 | WO |
2010111666 | Sep 2010 | WO |
2014150106 | Sep 2013 | WO |
Entry |
---|
Ad et al., “A one way valved atrial septal patch: A new surgical technique and its clinical application”, The Journal of Thorasic and Cardiovascular Surgery, vol. 111, Apr. 1996, pp. 841-848. |
Althoff et al., “Long-Term Follow up of a Fenestrated Amplatzer Atrial Septal Occluder in Pulmonary Arterial Hypertension,” Chest 2008, 133:183-85, 5 pages. |
Atz et al., “Preoperative Management of Pulmonary Venous Hypertension in Hypoplastic Left Heart Syndrome With Restrictive Atrial Septal Defect”, The American Journal of Cardiology, vol. 83, Apr. 15, 1999, pp. 1224-1228. |
Bailey, “Nanotechnofogy in Prosthetic Heart Valves,” approx. date 2005, presentation, 31 pages. |
Bolling, “Direct Flow Medical—My Valve is Better.” Apr. 23, 2009, presentation, 21 pages. |
Cheatham, John P., “Intervention in the critically ill neonate and infant with hypoplastic left heart syndrome and intact atrial septum”, Journal of Interventional Cardiology, vol. 14, No. 3, 2001, pp. 357-366. |
Coselli, Joseph S., “No! valve replacement: patient prosthetic mismatch rarely occurs,” Texas Heart insitute, Apr. 25, 2009, 75 pages. |
Design News, “Low Power Piezo Motion”, http://www.designnews.com/document.asp?doc-id=229053&dfpPParams&dfpPParams=ht-13,aid-229053&dfpLayout=article, May 14, 2010, 3 pages. |
European Application Serial No. EP10772411.4, European Search Opinion and Supplementary European Search Report dated Mar. 16, 2012, 5 pages. |
European Application Serial No. EP12180631.9, European Search Report dated Nov. 19, 2012, 5 pages. |
Gaudiani et al., “A Philosophical Approach to Mitral Valve Repair,” Apr. 24, 2009, presentation, 28 pages. |
Hijazi, “Valve Implantation, Ziyad M, Hijazi,” May 10, 2007, presentation, 36 pages. |
International Application Serial No. PCT/AU2007/001704, International Pretiminaty Report on Patentability, dated Aug. 22, 2008, 5 pages. |
International Application Serial No. PCT/AU2007/001704, International Search Report, dated Jan. 16, 2008, 4 pages. |
International Application Serial No. PCT/AU2007/001704, Written Opinion, dated Jan. 16, 2008, 5 pages. |
International Application Serial No. PCT/US2010/026574, International Preliminary Report on Patentability, dated Nov. 10, 2011, 6 pages. |
International Application Serial No. PCT/US2010/020574, International Search Report, dated Nov. 19, 2010, 5 pages. |
International Application Serial No. PCT/US2010/058110, international Preliminary Report on Patentability, dated Nov. 27, 2012, 7 pages. |
International Application Serial No. PCT/US2010/058110, International Search Report and Written Opinion, dated Aug. 26, 2011, 12 pages. |
International Application Serial No. PCT/US2011/022895, International Search Report & Written Opinion, dated Oct. 24, 2011, 10 pages. |
International Application Serial No. PCT/US2011/041841, International Preliminary Report on Patentability and Written Opinion, dated Jun. 6, 2013, 7 pages. |
International Application Serial No. PCT/US2011/041841, International Search Report and Written Opinion, dated Feb. 9, 2012, 10 pages. |
International Application Serial No. PCT/US2012/024680, International Preliminary Report on Patentability and Written Opinion, dated Aug. 22, 2013, 6 pages. |
International Application Serial No. PCT/US2012/024680, International Search Report and Written Opinion, dated Oct. 23, 2012, 10 pages. |
International Application Serial No. PCT/US2012/071588, International Search Report and Written Opinion, dated Apr. 19, 2013, DC Devices, Inc., 17 pages. |
Larios et al., “The Use of an Artificial Foraminal Valve Prosthesis in the Closure of Interatrial and Interventricular Septal Defects.” Dis. Chest. 1959: 36; 631-41, 11 pages. |
Leon, “Transcatheter Aortic Valve Therapy: Summary Thoughts,” Jun. 24, 2009, presentation, 19 pages. |
Merchant et al., “Advances in Arrhythmia and Electrophysiology: Implantable Sensors for Heart Failure”, Circ. Arrhythm, Electrophysiol,, vol. 3, Dec. 2010, pp. 657-667. |
Moses, “The Good, the Bad and the Ugly of Transcatheter AVR,” Jul. 10, 2009, presentation, 28 pages. |
O'Loughlin et al., “Insertion of a Fenestrated Arnpiatzer Atrial Sestosotomy Device for Severe Pulmonary Hypertension,” Heart Lung Circ. 2006, 15(4):275-77, 3 pages. |
Park et al., “Blade atrial septostomy: collaborative study”, Circulation, Journal of the American Heart Association, vol. 66, No. 2, Aug. 1982, pp. 258-266. |
Pedra et al., “Stent Implantation to Create Interatrial Communications in Patients With Complex Congenital Heart Disease”, Catheterization and Cardiovascular interventions 47, Jan. 27, 1999, pp. 310-313, |
Perry et al., “Creation and Maintenance of an Adequate Interatrial Communicationin left Atrioventricular Valve Atresia or Stenosis”, The American Journal of Cardiology, vol. 58, Sep. 15, 1986, pp. 622-626. |
Philips et al, “Ventriculofemoroatrial shunt: a viable alternative for the treatment of hydrocephalus”, J. Neurosurg., vol. 86, Jun. 1997, pp. 1063-1068. |
Sommer et al., “Transcatheter Creation of Atrial Septal Defect and Fontan Fenestration with “Butterfly” Stent Technique”, Supplement to Journal of the American College of Cardiology, vol. 33, No. 2, Supplement A, Feb. 1999, 3 pages. |
Stone, “Transcatheter Devices for Mitral Valve Repair, Surveying the Landscape,” Jul. 10, 2009, presentation, 48 pages. |
Stormer et at, “Comparative Study of in vitro Flow Characteristics between a Human Aortic Valve and a Designed Aortic Valve and Six Corresponding Types of Prosthetic Heart Valves,” Eur. Surg. Res. 6: 117-131 (1976), 15 pages. |
Watterson et al., “Very Small Pulmonary Arteries: Central End-to-Side Shunt”, Ann. Thorc. Surg., vol. 52, No. 5, Nov. 1991, pp. 1132-1137. |
Number | Date | Country | |
---|---|---|---|
20140277045 A1 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
61778382 | Mar 2013 | US |